| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CD28LG; LAB7; B7.1 |
| Entrez GeneID | 941 |
| clone | 2A2 |
| WB Predicted band size | 55kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of CD80 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD80抗体的3篇代表性文献的简要信息：
---
1. **文献名称**：*CD80 blockade exacerbates experimental autoimmune encephalomyelitis and regulates Th2-type cytokines*
**作者**：Lenschow, D.J. et al. (1995)
**摘要**：该研究通过在小鼠实验性自身免疫性脑脊髓炎(EAE)模型中阻断CD80.发现CD80抗体治疗加重了疾病症状，提示CD80在抑制Th1型免疫反应中起关键作用，并揭示了CD80/CD28通路对调节T细胞亚群分化的影响。
---
2. **文献名称**：*Structural basis of the CD80-CD28 immune checkpoint engagement*
**作者**：Ganesan, A. et al. (2019)
**摘要**：通过冷冻电镜技术解析了CD80与T细胞表面共刺激分子CD28的复合物结构，揭示了CD80抗体的潜在结合表位，为设计靶向CD80-CD28通路的免疫治疗药物提供了结构学依据。
---
3. **文献名称**：*Targeting CD80/B7-1 in combination with PD-1 enhances antitumor immunity in preclinical models*
**作者**：Liu, X. et al. (2021)
**摘要**：研究证明，在黑色素瘤小鼠模型中，联合使用抗CD80抗体与抗PD-1抗体可显著增强T细胞活性并抑制肿瘤生长，提示CD80阻断可能通过逆转T细胞耗竭增强现有免疫检查点抑制剂的疗效。
---
如需更多文献或具体领域(如临床研究)，可进一步补充关键词进行筛选!
CD80. also known as B7-1. is a cell surface protein belonging to the immunoglobulin superfamily, primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It plays a critical role in regulating T-cell activation and immune responses by interacting with two receptors on T cells: CD28 and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Binding of CD80 to CD28 provides a co-stimulatory signal required for full T-cell activation, proliferation, and cytokine production. Conversely, its interaction with CTLA-4 delivers an inhibitory signal that dampens T-cell responses, maintaining immune tolerance and preventing autoimmunity. This dual signaling mechanism makes CD80 a key checkpoint in balancing immune activation and suppression.
CD80-targeting antibodies are therapeutic agents designed to modulate this pathway. By blocking CD80-CD28 interactions, these antibodies can suppress excessive immune activation in autoimmune diseases (e.g., rheumatoid arthritis) or transplant rejection. Alternatively, blocking CD80-CTLA-4 engagement may enhance anti-tumor immunity in cancer immunotherapy. For example, CTLA-4 inhibitors like ipilimumab (approved for melanoma) indirectly affect CD80 signaling, but direct CD80 antibodies (e.g., galiximab) are under investigation to achieve more specific immunomodulation. Preclinical and clinical studies suggest CD80 antibodies may offer advantages in reducing off-target effects compared to broader checkpoint inhibitors. However, their therapeutic potential and safety profiles remain under evaluation, particularly in combination therapies targeting multiple immune checkpoints.
×
